Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Oncology Consultants

Neither a doctor nor a teaching hospital

Research payments

$4,917,993

280 payments

Through program year 2025, Oncology Consultants is reported as receiving $4,917,993 in research payments, across 280 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $353,687 45
2024 Research $1,128,227 17
2023 Research $1,401,157 39
2022 Research $435,272 107
2021 Research $1,005,266 34
2020 Research $367,644 27
2019 Research $226,741 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $1,806,151 8 payments
  2. Merck Sharp & Dohme Corporation $1,254,106 17 payments
  3. Janssen Research & Development, LLC $639,069 62 payments
  4. Aadi Bioscience, Inc. $292,641 4 payments
  5. AstraZeneca Pharmaceuticals LP $150,555 5 payments
  6. Ipsen Bioscience Inc $117,673 4 payments
  7. Novartis Pharmaceuticals Corporation $113,836 6 payments
  8. Kyowa Kirin, Inc. $112,863 70 payments
  9. Genentech, Inc. $111,662 11 payments
  10. TerSera Therapeutics LLC $110,801 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. AMG 510 Ph1b Master Protocol 20190135 $1,551,311 4 payments
  2. TACTI-002 Two ACTive Immunotherapeutics A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer NSCLC, or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer HNSCC receiving the soluble LAG-3 fusion protein eftilagimod alpha IMP321 in combination with pembrolizumab PD-1 antagonist $724,467 3 payments
  3. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer $352,931 42 payments
  4. Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) $255,362 1 payment
  5. A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) $253,503 2 payments
  6. TACTI-002 Two ACTive Immunotherapeutics# A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer NSCLC, or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer HNSCC receiving the soluble LAG-3 fusion protein eftilagimod alpha IMP321 in combination with pembrolizumab PD-1 antagonist $221,253 2 payments
  7. A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non Small Cell Lung Cancer $211,366 14 payments
  8. TACTI-002 Two ACTive Immunotherapeutics A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer NSCLC, or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer HNSCC receiving the soluble LAG-3 fusion protein eftilagimod alpha IMP321 in combination with pembrolizumab PD-1 antagonist $168,534 4 payments
  9. An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas $117,673 4 payments
  10. Ipatasertib in Combination With Paclitaxel in TNBC and HR Breast Cancer $111,662 11 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record